1. (Currently amended) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:1331, or a purified polypeptide comprising a contiguous amino acid sequence with at least 70% sequence identity to the amino acid sequence of SEQ ID NO:1331, wherein the polypeptide comprises at least one antigenic determinant that elicits an immune response against Neisserial bacteria and has a length of 100 amino acids or less.

2-6. (Canceled).

7. (Withdrawn) An antibody which recognises the polypeptide according to claim 1.

8. (Canceled).

9. (Withdrawn) Nucleic acid encoding the polypeptide of claim 1.

10. (Previously presented) A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable vehicle.

11-12. (Canceled).

13. (Withdrawn) A method of treating a patient, comprising administering to the patient a therapeutically effective amount of a composition according to claim 10.

14. (Canceled).

15. (Withdrawn) A composition comprising the antibody of claim 7 and a pharmaceutically acceptable vehicle.

16. (Canceled).

17. (Withdrawn) A composition comprising the nucleic acid of claim 9 and a pharmaceutically acceptable vehicle.

18. (Canceled).

19. (Withdrawn) A method of treating a patient, comprising administering to the patient a therapeutically effective amount of a composition according to claim 15.

20. (Canceled).

21. (Withdrawn) A method of treating a patient, comprising administering to the patient a therapeutically effective amount of a composition according to claim 17.

22. (Canceled).

23. (Withdrawn) A method of detecting the presence of a meningococcal protein in a biological sample comprising contacting the biological sample with the antibody of claim 7.

24. (Withdrawn) A method of detecting the presence of a meningococcal antibodies in a biological sample comprising contacting the biological sample with the polypeptide of claim 1.

25. (Previously presented) The polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1331 and further wherein the polypeptide has a length of 100 amino acids or less.

26. (Previously presented) The polypeptide of claim 25, wherein the polypeptide has a length of 50 amino acids or less.

27. (Previously presented) The polypeptide of claim 25, wherein the polypeptide has a length of 25 amino acids or less.

28. (Previously presented) The polypeptide of claim 25, wherein the polypeptide has a length of 20 amino acids or less.

29. (Previously presented) A composition comprising the polypeptide of claim 25 and a pharmaceutically acceptable vehicle.

30. (Previously presented) A composition comprising the polypeptide of claim 26 and a pharmaceutically acceptable vehicle.

31. (Previously presented) A composition comprising the polypeptide of claim 27 and a pharmaceutically acceptable vehicle.

32. (Previously presented) A composition comprising the polypeptide of claim 28 and a pharmaceutically acceptable vehicle.

33. (Withdrawn) A method of treating a patient, comprising administering to the patient a therapeutically effective amount of a composition according to claim 25.